EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria

Katrine Baumann iD, Astrid-Helene Ravn Jørgensen, Jennifer Astrup Sørensen, Ditte Georgina Zhang iD, Misbah Noshela Ghazanfar iD, Per Stahl Skov, Anders Woetmann, Christian Vestergaard, Marcus Maurer iD, Simon Francis Thomsen

Clinical & Experimental Allergy · 2023

DOI: 10.1111/cea.14402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Experimental Allergy, 2023. Verfasst von Katrine Baumann und 9 weiteren Autor:innen. Beteiligte Einrichtung: Urticaria Center of Reference and Excellence (UCARE), Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denm…. Hauptthemen laut MEDLINE: Chronic Urticaria, Anti-Allergic Agents, Urticaria. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chronic UrticariaAnti-Allergic AgentsUrticariaHumansOmalizumabBasophilsHistamine ReleaseChronic Disease

Substanzen

OmalizumabAnti-Allergic Agents

Autor:innen und Institutionen

  • Urticaria Center of Reference and Excellence (UCARE), Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark.
  • RefLab ApS, Copenhagen, Denmark.
  • LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
  • Urticaria Center of Reference and Excellence (UCARE), Department of Dermatology and Venerology, Aarhus University Hospital, Aarhus, Denmark.
  • Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany.

ORCID-Profile: Katrine Baumann, Ditte Georgina Zhang, Misbah Noshela Ghazanfar, Marcus Maurer

Förderung

  • Novo Nordisk Fonden

Zitieren

APA

Baumann, K., Jørgensen, A. R., Sørensen, J. A., Zhang, D. G., Ghazanfar, M. N., Skov, P. S., Woetmann, A., Vestergaard, C., Maurer, M., & Thomsen, S. F. (2023). Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14402

Vancouver

Baumann K, Jørgensen AR, Sørensen JA, Zhang DG, Ghazanfar MN, Skov PS, et al. Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria. Clinical & Experimental Allergy. 2023. doi:10.1111/cea.14402

BibTeX
@article{Baumann2023,
  author = {Baumann, Katrine and Jørgensen, Astrid-Helene Ravn and Sørensen, Jennifer Astrup and Zhang, Ditte Georgina and Ghazanfar, Misbah Noshela and Skov, Per Stahl and Woetmann, Anders and Vestergaard, Christian and Maurer, Marcus and Thomsen, Simon Francis},
  title = {Positive basophil histamine release assay predicts insufficient response to standard‐dosed omalizumab in patients with chronic spontaneous urticaria},
  journal = {Clinical & Experimental Allergy},
  year = {2023},
  doi = {10.1111/cea.14402}
}
Kostenlos starten →